PCS 499

Drug Profile

PCS 499

Alternative Names: CTP-499; PCS-499

Latest Information Update: 04 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Concert Pharmaceuticals
  • Class Anti-inflammatories; Antifibrotics; Organic deuterium compounds; Small molecules
  • Mechanism of Action Antioxidants; Phosphoric diester hydrolase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Necrobiosis lipoidica
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Diabetic nephropathies; Kidney disorders

Most Recent Events

  • 02 Oct 2018 The US FDA approves IND application for a phase II trial of PCS 499 in Necrobiosis lipoidica
  • 22 Jun 2018 PCS 499 receives Orphan Drug status for Necrobiosis lipoidica in USA
  • 22 Jun 2018 Processa Pharmaceuticals announces intention to submit NDA to the US FDA for Necrobiosis lipoidica in 2020-2022
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top